When was Bion Clinicals founded?

Bion Clinicals was founded in 2022.

Where is Bion Clinicals located?

Bion Clinicals is headquartered in Pune, India.

Is Bion Clinicals a funded company?

Bion Clinicals is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Bion Clinicals rank among its competitors?

Bion Clinicals ranks 129th amongst 140 active competitors, only 1 of which is funded. Eluceda, which secured $1.5M in Jul, 2021.

Who are the top competitors of Bion Clinicals?

Bion Clinicals' top competitors include Fagron, Navitas Life Sciences and Pinnaxis. Among them, Eluceda secured the most recent funding round in July, 2021.

Bion Clinicals - 2026 Company Profile, Team & Competitors

Bion Clinicals is an unfunded company based in Pune (India), founded in 2022 by Bagde and Sachin Mane. It operates as a Provider of bioequivalence, bioavailability studies, patient trials, and regulatory affairs. Bion Clinicals has not raised any funding yet. The company has 140 active competitors, including 1 funded and 9 that have exited. Its top competitors include companies like Fagron, Navitas Life Sciences and Pinnaxis.

Company Details

Provider of bioequivalence, bioavailability studies, patient trials, and regulatory affairs. They offer services including medical writing and validated method publications. The organization supports pharmaceutical product development through clinical research. They specialize in understanding regulatory perspectives in bioequivalence studies.

Key Metrics

Founded Year

2022

Location

Pune, India

Stage

Unfunded

Ranked

129^th among 140 active competitors

Similar Companies

Fagron & 139 more

View Bion Clinicals' full profile

Bion Clinicals has not raised any funding rounds yet.

The founders of Bion Clinicals are Bagde and Sachin Mane.

Here are the details of Bion Clinicals' key team members:

Bagde: Founder Director and Head CRO of Bion Clinicals.
Sachin Mane: Founder Director Bion Clinicals Private Limited of Bion Clinicals.

View details of Bion Clinicals's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bion Clinicals include Fagron, Navitas Life Sciences and Pinnaxis. Here is the list of Top 10 competitors of Bion Clinicals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Fagron 1990, Rotterdam (Netherlands), Public	Provider of pharmaceutical compounding, sterile outsourcing services, and related pharmaceutical products	-	Triodos Investment Management, Baltisse & 2 others	51/100
2nd	Navitas Life Sciences 1986, Princeton (United States), Acquired	Technology-driven CRO providing end-to-end clinical, regulatory, and safety solutions	-	Orbimed, IIML	47/100
3rd	Pinnaxis 2018, Noida (India), Unfunded	Provider of pharmacovigilance services	-	-	39/100
4th	Freyr Solutions 2020, Princeton (United States), Unfunded	Provider of software for structured product labeling and product monographs	-	-	39/100
5th	Vizenlifesciences India, Unfunded	End-to-end pharmacovigilance services ensuring patient safety and regulatory compliance	-	-	37/100
6th	PMDA 2004, Chiyoda City (Japan), Unfunded	Provider of services related to pharmaceuticals, medical devices, and regenerative medicine	-	-	37/100
7th	Centice 2004, Morrisville (United States), Deadpooled	Computational sensor technology	$40.8M	Quantum Wave Fund, Fulcrum Equity Partners ... & 7 others	34/100
8th	Pharmacorp 2009, Pretoria (South Africa), Unfunded	Provider of medicine registration services	-	-	34/100
9th	Billev Pharma ApS 1978, Horsholm (Denmark), Unfunded	Consultancy company specializing in pharmaceutical and medical field services	-	-	34/100
10th	Eluceda 2009, Burnley (United Kingdom), Seed	Provider of pharmaceutical consulting and chemical testing services	$1.5M	UK Research and Innovation, Made Smarter	33/100
129th	Bion Clinicals 2022, Pune (India), Unfunded	Provider of bioequivalence, bioavailability studies, patient trials, and regulatory affairs	-	-	16/100